[{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"945e49ad-157e-4566-89d3-6b4ba4498abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04696029","created_at":"2021-01-19T20:49:35.193Z","updated_at":"2024-07-02T16:35:10.980Z","phase":"Phase 2","brief_title":"DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma","source_id_and_acronym":"NCT04696029","lead_sponsor":"Giselle Sholler","biomarkers":" TP53 • MYC • MYCN","pipe":" | ","alterations":" TP53 mutation • MYCN amplification • TP53 amplification","tags":["TP53 • MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYCN amplification • TP53 amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-04-08"},{"id":"177f8b5d-8348-4b32-a118-0b00e538da2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431582","created_at":"2022-06-24T15:56:46.001Z","updated_at":"2024-07-02T16:35:45.607Z","phase":"Phase 1","brief_title":"Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors","source_id_and_acronym":"NCT05431582","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CCNE1","pipe":" | ","alterations":" TP53 mutation • CCNE1 amplification • TP53 amplification","tags":["TP53 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CCNE1 amplification • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • azenosertib (ZN-c3)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 12/14/2022","primary_completion_date":" 12/14/2022","study_txt":" Completion: 12/14/2022","study_completion_date":" 12/14/2022","last_update_posted":"2023-06-15"}]